Introduction
Chronic myeloid leukemia (CML) is characterized by the presence of Philadelphia (Ph) chromosome, 1 which is observed in more than 95% of CML patients. This chromosome is the result of a reciprocal translocation, t(9;22) (q34;q11), which juxtaposes 3Ј DNA sequences of the abl gene mapping on 9q34.1 with 5Ј DNA sequences of the bcr gene mapping on 22q11. Even among Ph-negative CML patients, the bcr/abl rearrangement is present. Thus, Ph chromosome or the bcr/abl fusion gene serves as the hallmark of CML and also as a prognostic marker during the treatment of CML with interferon or bone marrow transplantation (BMT).
Until recently, detection of Ph chromosome has been primarily done by karyotype analysis of freshly obtained bone marrow cells. The major limitation of the karyotypic technique is an absolute need for metaphases in testing cells. However, it is difficult to obtain an appropriate number of metaphases, especially from patients under therapy. Therefore, about 20 or so cells are analyzed. Besides, since the technique is timeconsuming, it requires several weeks until a complete report is available in routine clinical practice in Japan.
The bcr/abl fusion gene can be detected by Southern blot analysis or by in vitro amplification of the bcr/abl specific RNA with the reverse-transcriptase polymerase chain reaction (RT-PCR). Southern blot analysis is no more sensitive than karyotype analysis. The RT-PCR technique is much more sensitive and can detect one abnormal cell in 10 4 to 10 5 cells. However, the RT-PCR is principally qualitative and not reliably quantitative and thus unsuitable for the monitoring of Ph-positive CML cells during therapy.
Fluorescent in situ hybridization (FISH) is a sensitive and quantitative method to detect specific chromosomal aberrations, not only in cells undergoing metaphase but in interphase nuclei as well. 8, 9 Besides, recently introduced twocolor FISH enables us to determine the copy number of a targeted sequence and the structural change by simply counting hybridization signals. Although this analysis provides only limited information about karyotype, it offers unique advantages and particular applications in the diagnosis and management of patients with CML.
Although several investigators have reported that the twocolor interphase FISH could identify Ph-positive cells in peripheral blood, as well as in bone marrow in patients with CML, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] there has been no study in a sufficient number of CML patients except one published recently. 21 Here, presenting the data of simultaneously performed RT-PCR, we also report that interphase FISH analysis in peripheral blood is a very simple and reliably sensitive technique for the diagnosis of CML, as well as for the quantitative monitoring of leukemia cell population during therapy. We propose that this peripheral blood FISH should first be applied as a screening test for differential diagnosis of CML in patients with moderate leukocytosis prior to the karyotype analysis of bone marrow cells.
Materials and methods

Patients and healthy volunteers
Patients with CML at various stages of disease were studied. Patients had been treated with interferon-␣ (IFN-␣) and/or hydroxyurea or other chemotherapy, or by BMT from HLAidentical siblings. Individuals with mild leukocytosis as well as healthy volunteers with normal leukocyte counts were also examined. After informed consent, peripheral blood was obtained, and in some patients bone marrow was simultaneously aspirated.
Fluorescence in situ hybridization (FISH)
Hybridization and detection were performed as described previously, 10 using the M-BCR-ABL translocation DNA probe mixture (Oncor, Gaithersberg, MD, USA), which detected t(9;22) with a breakpoint within the major breakpoint cluster region (M-bcr). The hybridization signals were evaluated using a fluorescence microscope with triple-pass filters (Nikon, Tokyo, Japan). At least 500 cells without damaged nuclei were blindly counted in each sample. Unhybridized cells were less than 1%, and only those spots with similar size, intensity and shape were counted. Cells with a yellow spot, ie fused green and red signals, were interpreted as positive for t (9;22) . Thus, a Ph-positive cell had one red, one green and one yellow spot, and a Ph-negative cell had two red and two green spots.
Karyotype analysis
Karyotype analysis was performed on 24-h cultured bone marrow samples, and 20 metaphases were analyzed for G-bands using trypsin-Giemsa techniques, according to standard procedures.
RNA extraction and reverse-transcriptase polymerase chain reaction
Total RNA was extracted as previously described. 22 Five micrograms of total RNA was reverse-transcribed with AMV reverse transcriptase according to the manufacturer's instruction (Bethesda Research, Gaithersberg, MD, USA). PCR reaction was performed by the following temperature-time profile: for 1 min at 94°C, 45 s at 55°C and 1 min at 72°C for 35 cycles, followed by an additional 7 min at 72°C. To amplify ␤-actin cDNA, the following primers were used: the sense primer, 5Ј-CTTCTACAATGAGCTGCGTG-3Ј; the anti-sense primer, 5Ј-TCATGAGGTAGTCAGTCAGG-3Ј, and to amplify M-bcr/abl cDNA, the sense primer, 5Ј-GGAGCTGCA-GATGCTGACCAAC-3Ј; the anti-sense primer, 5Ј-GGTCATTTTCACTGGGTCCAGC-3Ј. To amplify m-bcr/abl cDNA, the following primers were used: the sense primer, 5Ј-CGCATGTTGCGGGACAAAAGC-3Ј; the anti-sense primer, 5Ј-GGTCATTTTCACTGGGTCCAGC-3Ј. Cross -contamination was prevented as recommended by Kwok and Higuchi. 23 Then, PT-PCR products were analyzed on 3% agarose gels, and transferred on a nylon membrane (Biodyne B Membrane, 0.45 m, Pall Biosupport, NY, USA). Blots were hybridized with ␥-32 P-labeled probes: b11a2 (5Ј-GCTGAAGGG-CTTCTTCCTTATTGATG-3Ј) and b12a2 (5Ј-GCTGAA-GGGCTTTTGAACTCTGCTTA-3Ј) for M-bcr, and b1a2 (5Ј-GCTGAAGGGCTTCTGCGTCTCCAT-3Ј) for m-bcr, and were exposed to HR-HA film (Fuji, Tokyo, Japan).
Statistical methods
The correlation was evaluated using the Pearson's correlation coefficient and the lineal regression analysis, and also the limits of agreement 24 were calculated. The false-positive yellow spots most likely derived from accidental colocalization of red and green spots as a result of the projection of two genes located one above another into a plane. 25 We named the positive cells as FISH-positive cells, and defined that the M-bcr/abl fusion gene was present in the peripheral blood, if more than 4.8% (mean + 3 s.d.) cells were FISH-positive in 500 cells examined.
Results
False
False-positive detection of M-bcr/abl fusion gene by FISH in bone marrow of healthy volunteers and patients without hematological malignancies
We also tested 20 bone marrow samples from healthy sibling donors for BMT and patients without hematological malignancies. Positive cells were observed in 2.3 ± 0.7% (range, 1.1 to 3.5%) cells in more than 500 nucleated bone marrow cells examined. Therefore, we defined that the M-bcr/abl fusion gene was present in the bone marrow, if more than 4.4% (mean + 3 s.d.) cells were FISH-positive in 500 cells examined.
Detection of M-bcr/abl fusion gene by FISH and RT-PCR in patients with CML
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ever, the difference between the percentages was −3.5 ± 16.1%, and thus the limits of agreement were not small. In all six patients who underwent allogeneic BMT, FISHpositive cells for the M-bcr/abl fusion gene in the peripheral blood were under the cutoff level, ie 4.8% or less. Ph chromosome in the bone marrow was negative by karyotype analysis in all four patients tested. FISH-positive cells for the M-bcr/abl fusion gene in the bone marrow were under the cutoff level, ie 4.4% or less, in three patients examined. RT-PCR was simultaneously tested in the peripheral blood of four patients, and was negative in all except one. The latter patient had 3.4% FISH-positive cells in the peripheral blood (negative for the M-bcr/abl fusion gene by our definition), 2.7% FISH-positive cells in the bone marrow (negative for the M-bcr/abl by our definition) and no Ph chromosome in 20 cells in metaphase in the bone marrow. The peripheral blood of this patient was once more tested 3 months later. The RT-PCR was again positive, but FISH-positive cells were 3.1% (again negative by our definition). Nonetheless, this patient is still in a complete hematological remission without any treatment up to 48 months after the first test for FISH and RT-PCR. and/or hydroxyurea had positive RT-PCR test in the peripheral blood when examined. In three patients who were treated with IFN-␣ therapy, both peripheral blood FISH and bone marrow karyotype were sequentially analyzed, and a good correlation was observed between the two analyses ( Table 1 ).
Although we simultaneously tested the peripheral blood of 25 CML patients for m-bcr/abl by RT-PCR, none of them had this fusion.
FISH-positive cells among neutrophils and lymphocytes in the peripheral blood of patients with CML
In 11 patients with CML in chronic phase who were under IFN-␣ therapy or after BMT and had 3 to 92.4% FISH-positive cells in the peripheral blood, the morphological characteristics of each FISH-positive cell were carefully examined (Table 3, Figure 4 ). Since the differential of peripheral leukocytes was not easy on the FISH preparation, mononuclear cells were first isolated by the Ficoll-Hypaque gradient centrifugation, and the FISH analysis was performed separately both on the mononuclear cell fraction and on the neutrophil fraction. Additionally, we made every effort to differentiate these isolated cells by morphological characteristics. In Table 3 , the lymphocyte fraction may contain some other mononuclear cells such as monocytes and immature granulocytes, but the percentage of contaminated immature granulocytes would be minimal, since nine patients had less than 8500/l leukocytes and two other patients had 22 900 and 26 700/l leukocytes, respectively, and their neutrophil fraction consisted mostly of band or segmented neutrophils. In the former nine patients with leukocyte counts less than 8500/l with no immature granulocytes, the percentage of FISH-positive cells in the lymphocyte fraction was always lower than that in the neutrophil fraction except one patient after BMT who had 3.3% and 2.9% of FISH-positive cells, respectively. In the latter two patients with higher leukocyte counts, 69% and 90% of the cells were FISH-positive. Mean ± s.d. of FISH-positive cells in whole leukocyte, neutrophil and lymphocyte fractions of these 11 CML patients were 57.4 ± 29.9, 72.6 ± 32.3 and 40.0 ± 27.6, respectively. Thus, careful interpretation will be 
Screening of individuals with mild leukocytosis for the M-bcr/abl fusion gene by the FISH analysis in the peripheral blood
Fifteen individuals with mild leukocytosis were tested for the M-bcr/abl fusion gene by FISH analysis of the peripheral blood, when they were referred to us because of leukocytosis, which had been accidentally discovered during their annual health checkup. Their leukocyte counts ranged from 10 000 to 12 900/l with a median of 10 900/l. They were all male, and their age ranged from 26 to 52 years with a median of 37. FISH-positive cells in the peripheral blood ranged from 1.0 to 3.0%, with a median of 2.2%. Two of them, who had 1.6% and 2.9% FISH-positive cells, were confirmed to be negative for the M-bcr/abl gene by the RT-PCR. As shown in Tables 1 and 2 , FISH-positive cells in the peripheral blood were above the cut-off level in all CML patients with leukocyte counts more than 5000/l, unless they underwent BMT. Therefore, we judged the rest of these individuals were negative for the M-bcr/abl fusion gene, and performed neither bone marrow examination nor the leukocyte alkaline phosphatase staining. None of them showed progressive increase of their leukocytes up to 2-years' observation, although some still have mild leukocytosis.
Discussion
Ph chromosome is the hallmark of CML, and its identification is essential for the diagnosis of this disease. Ph chromosome also serves as an important end point in the monitoring of treatment response to interferon therapy or BMT. Patients often obtain complete cytogenetic response to interferon therapy, ie no Ph chromosome by karyotype analysis of the bone marrow cells, 26 and live longer than those without cytogenetic response. 27, 28 However, to do karyotype analysis, we must first perform a bone marrow aspiration, a painful procedure for patients. Besides, metaphases are requisite for the analysis, but more than 20 to 25 metaphases are difficult to obtain in patients under chemotherapy and/or interferon therapy. Thus, in routine clinical practice, about 20 or so metaphases are generally analyzed, and if no Ph chromosome was found among 20 cells, it was defined as a complete cytogenetic response, 26 although this is not statistically reliable. Additionally, karyotyping is extremely time-consuming, and in Japan it takes usually several weeks to get a complete report with fully classified karyotypes.
Both Southern blot analysis and RT-PCR of the M-bcr/abl fusion gene are mainly qualitative and not reliably quantitative, and thus they are unsuitable for routine monitoring of the degree of treatment response. However, Vershraegen et al 29 reported that Southern blotting can be quantified by densitometric analysis of autoradiographic exposures on peripheral blood samples, and that the correlation between the bcr quantification and the percentage of Ph chromosome was good (r = 0.78) in 465 CML samples. Although Southern blotting overestimated the degree of response in samples with a minor or no cytogenetic response, they stated that this molecular quantification in peripheral blood was useful in monitoring the course of CML. 29 Stock et al 30 also reported that a quantitative Southern blot analysis for peripheral blood samples might substitute for karyotype analysis of bone marrow cells in the monitoring of treatment response in CML. However, there is also some overestimation on the degree of response to therapy, and they recommended that marrow karyotype analysis should be performed when patients achieved a complete response by Southern blot monitoring.
The unquestionable advantage for FISH is that analysis is quantitative and can be done on cells in interphase, which implies that we can perform this test on the peripheral blood leukocytes. A possible disadvantage for FISH is high false-positivity. Dewald et al 13 reported earlier that the normal range for the interphase bone marrow cells with apparent fusion signals was р10%. In the present study after considerable improvement of the technique, however, false positivity was less than 4% in both peripheral and bone marrow cells. Garcia-Isidoro et al 31 also reported 1.7 ± 0.9% false positivity by FISH in the bone marrow cells of 10 healthy individuals, van den Berg et al 32 between 1.0 and 1.4% in blood samples of several controls, and Mü hlman et al 21 1 ± 0.42% in the peripheral blood of 11 healthy controls. Thus, our 2.7 ± 0.7% false positivity in the peripheral blood of 30 healthy controls is not exceptional. We believe that our FISH system is as sensitive as the triple-probe three-color FISH system reported by Sinclair et al, 33 which showed 2.8 ± 0.82% false positivity in six normal bone marrow and peripheral blood samples, but is less sensitive than the hypermetaphase FISH reported by Seong et al 34, 35 and the double FISH reported by Dewald et al. 36 The hypermetaphase FISH, however, requires metaphases and thus obliges bone marrow aspiration. It may not therefore be suitable for routine monitoring in patients under therapy, since an appropriate number of metaphases is difficult to obtain in these patients. Simple and accurate analytical methods are essential for disease monitoring, and the peripheral blood FISH seems to be the most suitable and reliably sensitive method for this purpose.
Of seven patients with CML who underwent allogeneic BMT, the peripheral blood FISH-positive cells were under the cut-off level in all of them. In one of them, however, RT-PCR in the peripheral blood was positive. Both FISH and PT-PCR were repeated in the peripheral blood 3 months later, and again FISH-positive cells were under the cut-off level and RT-PCR was positive. This patient is in a complete hematological remission without any treatment up to 48 months after the first test. Since Biernaux et al 37 reported that the M-bcr/abl gene was detectable by RT-PCR at a very low level in peripheral blood cells of 22 of 73 healthy adults and one of 22 healthy children, this patient may belong to these RT-PCR-positive individuals. Most plausibly, however, these findings merely imply that RT-PCR is more sensitive than FISH and that this patient has a minimal residual disease and may eventually relapse. In spite of its high sensitivity, RT-PCR is not reliably quantitative at present. Thus, the FISH test may be more reliable clinically in the monitoring of the bcr/abl fusion gene in CML. 31, 32, [38] [39] [40] [41] Additionally, this peripheral FISH test is very useful in differential diagnosis of CML. Up to now, when patients or healthy individuals with leukocytosis were referred to hematologists, we have had to perform bone marrow aspiration and send the samples for karyotype analysis in order to confirm the diagnosis of CML. The peripheral blood FISH test will reliably differentiate CML from other diseases without performing bone marrow aspiration. In the present study, FISH-positive cells in the peripheral blood for the M-bcr/abl fusion gene were always above the cut-off level in CML with more than 5000/l leukocytes, unless they underwent BMT. Therefore, if patients have Ph-positive CML, FISH-positive cells in the peripheral blood should exceed the cut-off level in any patients with leukocytosis.
Use of a M-bcr probe alone would give little problem for the diagnosis of CML, since the simultaneous m-bcr testing was all negative in the present study. Moreover, we found only one patient with the m-bcr/abl fusion gene in over 300 CML patients who had hitherto been tested by either RT-PCR, FISH or Southern blotting in our laboratory. This patient was also positive for the M-bcr/abl fusion gene and therefore the chance of false-negativity would be minimal even if we had used an M-bcr probe alone.
At the time of diagnosis of CML, peripheral leukocytes are generally of leukemia origin, and not only granulocytes but also monocytes, erythroid cells, megakaryocytes and lymphocytes are reportedly positive for Ph chromosome. 2, [42] [43] [44] [45] There is some controversy over whether lymphocytes are of leukemia origin in CML. Garicochea et al 46 reported that T lymphocytes had no bcr/abl fusion gene, while Tefferi et al 42 demonstrated that t(9;22) was detectable in 34% of CD3-positive T lymphocytes, in 32% of CD19-positive B lymphocytes and in 82% of CD34-positive precursor cells. In the present study, one patient in blast crisis of CML had 100% FISH-positive cells in her peripheral blood, which consisted of blasts, immature and mature neutrophils, basophils, eosinophils, monocytes and lymphocytes. Furthermore, careful analysis of peripheral neutrophils and lymphocytes revealed that the FISHpositive cells were more frequent in the neutrophil fraction than in the lymphocyte fraction but the latter definitely had a bcr/abl fusion gene. The lower percentage of FISH-positive cells in the peripheral blood than in the bone marrow (mean difference, 7.9%) probably comes from these M-bcr/abl-negative lymphocytes. Therefore, careful interpretation will be required to evaluate patients with a low percentage of FISHpositive cells, and the bone marrow FISH test may give more reliable information for these patients.
Although there was a good correlation between the percentage of FISH positive cells in the peripheral blood and that in the bone marrow (r = 0.977), between the percentage of FISH positive cells in the peripheral blood and that of Ph chromosome in the bone marrow (r = 0.841) and between the percentage of FISH positive cells and that of Ph chromosome in the bone marrow (r = 0.933), the limits of agreement in each group were not small. Thus, the peripheral blood FISH test for the M-bcr/abl fusion gene can not be interpreted as the same method with the bone marrow FISH test and with the conventional Ph chromosome analysis in bone marrow cells. This is quite understandable because the analysis of the limits of agreement is a statistical method to assess agreement between a new measurement with an established one for the same data. 24 The FISH tests in the peripheral blood and in the bone marrow are basically not the same data due to different cell populations. Mü hlman et al 21 calculated the limits of agreement between an interphase FISH test in the peripheral blood and a hypermetaphase FISH technique in bone marrow, and concluded that there was a good agreement between the two methods. However, they analyzed at least 100 metaphases for the latter technique, which is usually impossible for conventional karyotyping. Since the confidence intervals for the limits of agreement are generally wide in small sample sizes, if we had analyzed more cells in metaphase and more cases, we might have reached a similar conclusion.
Our present study at least indicates that the FISH analysis for the M-bcr/abl fusion gene in the peripheral blood is a simple and reliably sensitive test for the diagnosis and monitoring of CML in routine clinical practice. However, since this analysis can not entirely replace karyotypic analysis of bone marrow cells, we will probably need different remission criteria based on the peripheral blood FISH test for the treatment response in CML. In the Japan Adult Leukemia Study Group, we are now conducting a prospective study on whether this peripheral blood FISH test can serve as a monitoring marker in the interferon therapy of CML.
